NEWS

NEWS

新闻资讯

Company news

Industry news

2026-05-25

Nanolattix Announces Three Studies Selected for the ASCO 2026 Annual Meeting, Highlighting International Recognition of Innovative RDC+ADC Paradigm

Nanolattix Announces Three Studies Selected for the ASCO 2026 Annual Meeting, Highlighting International Recognition of Innovative RDC+ADC Paradigm

Learn more

2025-07-09

Clinical Trial Recruitment for T320, a Novel TF-Targeting Anti-Cancer Drug

Clinical Trial Recruitment for T320, a Novel TF-Targeting Anti-Cancer Drug

Learn more

2025-07-09

Nanolattix’s T320-ADC Multi-Center Clinical Trials Initiated, Accelerating Development of Advanced Solid Tumor Therapies

Nanolattix’s T320-ADC Multi-Center Clinical Trials Initiated, Accelerating Development of Advanced Solid Tumor Therapies

Learn more

Media Focus | Tonacea: ADC Accelerates Iteration, RDC Gains Momentum – Trends at ASCO 2026 and Nanolattix‘s Strategic Logic

Media Focus | Tonacea: ADC Accelerates Iteration, RDC Gains Momentum – Trends at ASCO 2026 and Nanolattix‘s Strategic Logic

02

2026/06

Media Focus | Tonacea: Under the Dual-Mode Narrative, Nanolattix Launches a Synergistic Offensive

Media Focus | Tonacea: Under the Dual-Mode Narrative, Nanolattix Launches a Synergistic Offensive

27

2026/04

Nanolattix Chairman Qu Zhican Invited to Attend 3rd Radiopharmaceutical Development Summit, Collaborates to Shape RDC Innovation Landscape

Nanolattix Chairman Qu Zhican Invited to Attend 3rd Radiopharmaceutical Development Summit, Collaborates to Shape RDC Innovation Landscape

27

2026/03

Targeting Drug Resistance Challenges, Nanolattix's HER2/TF Bispecific ADC B836 Selected for AACR Session

Targeting Drug Resistance Challenges, Nanolattix's HER2/TF Bispecific ADC B836 Selected for AACR Session

27

2026/03

Nanolattix’s TF-Targeting Radiopharmaceutical RDC Selected for AACR, Accelerating Theranostic System Deployment

Nanolattix’s TF-Targeting Radiopharmaceutical RDC Selected for AACR, Accelerating Theranostic System Deployment

23

2026/03

Nanolattix Chairman Qu Zhican Invited to Attend 3rd Radiopharmaceutical Development Summit, Collaborates to Shape RDC Innovation Landscape

Nanolattix Chairman Qu Zhican Invited to Attend 3rd Radiopharmaceutical Development Summit, Collaborates to Shape RDC Innovation Landscape

23

2026/03